


A Study of Intravaginal Tablet Misoprostol (25µg) For Induction of Labour in Primigravida with Term Gestation



Gynaecology

KEYWORDS:

Dr. Rekhattha

Associate professor in department of obg Kanachur medical college , derlakatte

ABSTRACT

This study evaluates the safety and efficacy of intravaginal low dose (25µg) of Misoprostol for cervical ripening and labour induction in primigravida with term gestation. Two hundred and forty seven patients with an indication for induction of labour in third trimester were included. The cervical score was assessed by using Bishop's score prior to prostaglandin induction. Patient's with Bishop's score 0-5 were considered not significant. Misoprostol was significantly more effective in inducing labour (98%) with the number of failed induction being 5 out of 247. 94% of Patients delivered within 24 hours. Mean time from start to delivery (including caesarean) was 12.97+6.34hours. Lesser number of patients required oxytocin augmentation i.e. 32%. Induction to vaginal delivery interval was 11.9+4.9 hours. Induction to vaginal delivery interval was significantly greater with Bishop's score 3 i.e. 10.2+3.7 hours. 97.56% of patients delivered vaginally within 24 hours. 68.29% of patients delivered vaginally with single dose of Misoprostol with mean number of dose 1.34+0.52. Dystocia, non reassuring FHR with hyper stimulation and tachysystole were 2%, 4% and 4% respectively. Neonates with Apgar score of 40%), prolonged hospital stays and an overall increase in maternal and fetal morbidity. Misoprostol is a synthetic analogue (15 deoxy 16 hydroxy 16 methyl) of natural PGE₁, with a molecular weight of 382.54. The utero tonicity of this in pregnant women was first described in 1987. The use of Misoprostol for cervical softening and term labor induction was first reported by Margulies et al in 1992. Misoprostol acts as a myometrial stimulant of the pregnant uterus by selectively binding to prostaglandin E₂ sensitive receptor subtypes EP-2 and EP-3. It can be used orally as well as vaginally. Misoprostol is affordable, easily stored at room temperature. Dispersion in hydroxyl propyl methyl cellulose (1:100) enhances the stability of misoprostol. Therefore the conventional tablets of misoprostol can be produced with a shelf life of several years. In this study, efficacy and safety of intravaginal low dose (25µg) misoprostol for cervical ripening and labor induction is evaluated in primigravida with term gestation. 2. MATERIALS AND METHODS The study was done at KSHEMA & Sahara Hospital in Mangalore. The Criteria for inclusion in the study were Singleton pregnancy Cephalic presentation Unfavourable cervix (Bishop's score < 4) Clinically adequate pelvis No history of any uterine scar Patients not in labor Patients with no fetal distress. Two hundred and forty seven patients with an indication for induction of labor in third trimester and who gave informed consent were studied. After the recruitment to study, patients identification, data, history, physical examination, findings were noted in the designed pro forma. Pelvic examination was carried out to note the inducibility of cervix prior to the induction and during the course of labor to assess the progress of labor. Inducibility of cervix was assessed by Bishop's score (1964). All patients enrolled in the study received Misoprostol 25µg 4 hourly placed digitally in the posterior vaginal fornix under aseptic precaution for maximum of four doses. The second dose was withheld, if patients were having three or more regular uterine contractions in 10 minutes lasting for 30-60 seconds. Oxytocin was started if Bishop's score was more than 6 in the absence of adequate uterine contractions after 4 hrs of last dose; or for augmentation of labor in case of arrest of dilatation. Oxytocin was started at the dose of 2mU/min. with increments of 2mU/min. every 30 minutes. Membranes were ruptured, when the cervix was completely effaced with a cervical dilatation of >3 cms. The data collected included indication for induction, maternal age, parity, gestational age on entry into the study, insertion to delivery interval, duration of labour, number of patients delivered within 24 hrs, the occurrence of spontaneous labour, route and type of delivery, mean number of doses until delivery, number of patients delivered after a single dose, number of patients requiring oxytocin augmentation, maternal complication and neonatal complication, neonatal birth weight and Apgar scores at 1 and 5 minutes, etc. Student's t test was used for data analysis and P value of <0.05 was considered significant

Sl no	Patients characteristics	N=247
1	Age (yrs)	23.96+ 3.62
2	Gravidity	1.42+/- 0.7
3	Gestational age (weeks)	39.86+/-1.22
4	Bishop's score	193(78%)
	<3	54(22%)
	>3	

(Values are in mean +SD or in percentages)

The indication for induction in primigravida with term gestation is shown in Table 2

Sl no	Indications	N=247%
1	Post dates	46%
2	Hypertensive disorders	14%
3	Gestational diabetes	8%
4	IUGR	6%
5	Oligohydramnios	6%
6	PROM	4%
7	Decreased fetal movement	12%
8	Rh negative preg	4%
9	Others	-

The most common indication for induction of labor was post dated pregnancy i.e., 46%. Total vaginal deliveries were 82% out of which 93% were spontaneous deliveries and 7 % being operative vaginal deliveries. Out of total operative vaginal deliveries 67% were vacuum extractions and 33% outlet forceps. Indications for operative vaginal deliveries were non-reassuring fetal heart rate in late first stage of labour, hyperstimulation with fetal distress and failure of secondary forces during second stage of labour. Incidence of caesarean deliveries was 18%.

TABLE -3 Indications for caesarean section

Sl no	Indications	%
1	Fetal distress	78%
2	Dystocia	11
3	Failed induction	11

Indications for caesarean section was fetal distress (78%) dystocia (11%) failed induction (11%). Misoprostol was significantly more effective in inducing labour (98%) with the number of failed induction being 5 out of 247. 94% of patients delivered within 24 hrs. Mean time from start to delivery including caesarean section was 12.97+6.34. Significantly lesser number of patients required oxytocin augmentation (32%). Induction to vaginal delivery interval was 11.9+4.69hrs. 97.56% of patients delivered vaginally within 24 hrs. 68.29% of patients delivered vaginally with single dose of Misoprostol with mean number of dose being 1.34+0.52.

TABLE-4 Complications during Labor

Sl no	Complications	N=247%
1	Non reassuring FHR With hyperstimulation With dystocia With dystocia and hyperstimulation Without dystocia or hyperstimulation	4% 0 0 18%
2	Dystocia	2%
3	Tachysystole	4%
4	Vomiting	2%
5	PPH	2%

Fetal distress occurring in the late 1st stage or 2nd stage of labour either delivered spontaneously (10%) or by vacuum (10%) or forceps (10%) whereas those occurring in the early stage of labor delivered by caesarean section (70%). 2% of patients had vomiting during second stage of labour treated with IV fluids and anti emetics. 5 patients had Post Partum Haemorrhage requiring blood transfusion. Out of this 2 had atonic PPH responded to oxytocics and 1 unit of blood transfusion. 3 patients had traumatic PPH (Colporrhexis) requiring 2 units of blood transfusion and suturing under general anaesthesia

4. DISCUSSION

The earliest studies of the use of misoprostol for cervical ripening and labour induction were done by South American investigators(5). Results of our study are discussed under the following headings. Response to treatment, uterine response, operative delivery rate, maternal side effects, neonatal outcome. Response to treatment: a. Success Rate: In various randomized trials labor induction was considered successful if the patient were delivered vaginally within 24 hrs of initiation of misoprostol. The rate of successful induction in our study group was 97.56%. This is consistent with the studies of 6, 7, 8 who had success rate of 91%, 95% and 100% respectively.

Authors (year)	No. of Patients	Regimen	Success rate
1. Sanchez-Ramos et al (1998)	223	PGE1=50µg Intravaginally every 3hrs	71.3%
2. Kramer et al (1997)	130	PGE1=100µg Intravaginally every 4hrs	80%
3. Wing & Paul (1996)	522	PGE1=25µg Intravaginally every 3hrs PGE1=25µg Intravaginally every 6hrs	63.9% 55.4%
4. Sanchez-Ramos et al (1993)	129	PGE1=50µg Intravaginally every 4hrs	91%
5. Gottschall et al (1997)	75	PGE1=100 µg Intravaginally single dose	95%
6. Farah et al (1997)	399	PGE1=25 µg Intravaginally every 3hrs PGE1=50 µg Intravaginally every 6hrs	82% 84%
7. Wing et al (1994)	135	PGE1=50 µg Intravaginally every 3hrs	70.6%
8. Margulies et al (1992)	64	PGE1=50 µg Intravaginally single dose	79%

9. Chuck & Huffaker et al (1995)	99	PGE1=50 µg Intravaginally every 4hrs	100%
Present study	247	PGE1=25 µg Intravaginally every 4hrs	97.56%

The time taken from the stimulation of labor to its successful completion is the induction delivery interval. In our study induction to vaginal delivery interval was 11.9+4.9 hours. This is comparable to other studies shown in the table 5 except in a study 9 where they used 25µg of misoprostol every 3 hrly. Neonates with Apgar score of <= 7 at 1 min., 5 min. and incidence of thick meconium were 12%, 2%, 14% respectively. There was 1 still birth in a patient with severe PIH associated with IUGR at 38 weeks of gestation. In one of the studies 10, 399 patients received either 25µg or 50 µg of misoprostol intravaginally every 3hrs. There was significant difference between nulliparous and multiparous in both the groups. Multiparous patients receiving 50 µg. had short induction delivery interval (547 + 362 minutes Vs 706 + 442) compared to 25 µg. Patients with low inducibility rating had lower success rate, longer induction time and higher total dose of misoprostol.

b. Failed induction: In our study there was 5 (2%) failed inductions treated with caesarean section Uterine response: Hypertonus was defined as a single contraction lasting for at least 2 minutes. Tachysystole was defined as at least 6 contractions in 10 minutes for 2 consecutive 10 minutes period.

Hyperstimulation syndrome was defined as the presence of tachysystole or hypertonus associated with fetal tachycardia, late decelerations and/or loss of beat to beat variability.

In our study we had 4% incidence of tachysystole compared to incidences reported in literatures which varies from 4.2% 11 to 36.8% 9.

The Incidence of tachysystole was significantly decreased in the 25 µg group (7.4%) compared with the 50 µg group (36.8%) and 100 µg group (72%) but no adverse events reported as a consequence of tachysystole in any of the misoprostol studies 12.

The incidence of hyperstimulation syndrome in our study was 4%. No difference in the incidence of hyperstimulation syndrome was noted between 50 µg and 25 µg group which is 7.3% and 5.8% respectively (9).

Operative delivery rate: Misoprostol induction resulted in 7% operative vaginal delivery in our study. Caesarean section was 18% compared to 6 21.9%, 11 3.1%, 9 14.7%, 13 20.3%, 14 22.2%, 8 20.4%. Meta analysis 15 revealed that subjects receiving misoprostol had a lower caesarean rate than the control (15.6% Vs 21.5%; P < 0.02).

Maternal side effects: Gastrointestinal side effects were uncommon in our study group. Diarrhoea, fever, and chorioamnionitis were not seen. <3% incidence of pyrexia has been reported during labour after misoprostol administration for induction of labor 16 2% of our patients had PPH which is comparable to other studies i.e., 14 PGE1= 25 µg/3hrs 2.1% and PGE1=50 µg/3hrs 1.9%, 8 PGE1=50 µg q 4hrs 2%, 6 PGE1=50 µg q 4hrs 1.6%.

Miscellaneous side effects:

1. Tachycardia 11

2. Sensation of warmth in the vagina after placement of drug is uncommon 9.

3. Amniotic fluid embolism caused maternal death in one case probably related to prior amnioinfusion. 17.

4. Uterine rupture may occur in multipara even with lower dose of misoprostol (25 µg)13.

These side effects were not seen in our study.

Neonatal outcome

Incidence of neonates with Apgar score of ≤ 7 at 5 minutes was 2%. 12% neonates were admitted to intensive care unit in our study compared to 4.7% 6, 19.1% 9, 12.3% 18 and 8.7% 8.

Meta analysis found no difference in incidence of 5 minutes Apgar scores and admission to NICU between the misoprostol and control groups 6. Neonatal outcome was similar in both the groups (PGE1 and PGE2 groups). Cord blood acid base analysis did not differ between the groups. No neonate met the ACOG criteria for birth asphyxia¹³

Complications like hyperbilirubinemia and meconium aspiration syndrome were not seen in our study compared to 9, 19, 15 i.e., 0.8% and 6.1%, 6.0% and 4.4%, 13.1% and 1.0% respectively

5. CONCLUSIONS

Misoprostol is an inexpensive drug. It is stable at room temperature and has got a long shelf life. It is easy to administer, safe and convenient for patients because they do not require bed rest, they can sit or move around freely and even carry out their routine activities at home until the beginning of labour. It holds a great promise for the developing and tropical countries like ours.

REFERENCES

- [1] Pearson JF, Andrews J. Induction of labour. The case for a low rate. In : Beard RW, Paintin DB (eds) Outcome of obstetrics intervention in Britain. RCOG publication 1980. pp. 137-149.
- [2] Tipton RH, Lewis BV. Induction of labour and perinatal mortality. Br Med J 1975; 1: 391-393.
- [3] Arulkumar S, Gibb DMF, Tambyraja RL, Heng SH, Ratnam SS. Total Uterine activity in induced labour – an index of cervical and pelvic tissue resistance. Br J Obstet Gynaecol 1985; 92:693.
- [4] Bamigboye AA, Hofmeyr GJ, Merrell DA. Rectal Misoprostol in the prevention of post partum haemorrhage: A placebo controlled trial. Am J Obstet Gynecol 1998; 179:1043-6.
- [5] Margulies M, Perez MC, Vato L. Misoprostol to induce labour. Lancet 1992; 339:64.
- [6] methyl analogue misoprostol versus oxytocin A randomized trial. Obstet Gynaecol 1993; 81: 332-6.
- [7] Gottschall DS, Borgida AF, Mihalek JJ, Sauer F, Rodis JE. A randomized clinical trial comparing misoprostol with prostaglandin E2 gel for preinduction cervical ripening. Am J Obstet Gynecol 1997; 177:1067-74.
- [8] Chuck FJ, Huffaker BJ. Labour induction with intravaginal misoprostol versus intracervical prostaglandin E2 gel: A randomized comparison. Am J Obstet Gynaecol 1995; 173: 1137-42.
- [9] Wing DA, Jones MM, Rahall A, Goodwin TM, Paul RH. A comparison of misoprostol and prostaglandin E2 gel for preinduction cervical ripening and labour induction. Am J Obstet Gynecol 1995a; 172: 1804-10.
- [10] Farah LA, Sanchez-Ramos L, Rosa C, Delvalle GO, Gaudier FL, Delka F, Kaunitz AM. Randomized trial of two doses of prostaglandin E1 analog misoprostol for labour induction. Am J Obstet Gynecol 1997; 177:384-71.
- [11] Fletcher H, Mitehell S, Frederick J, Simeon D, Brown D. Intravaginal Misoprostol versus Dinoprostone, As cervical ripening and labour inducing agents. Obstet Gynecol 1994; 83:244-7.
- [12] Kramer RL, Gilson GJ, Morrison DS, Martin D, Gonzales JL and Qualls CR. A randomized trial of Misoprostol and Oxytocin for induction of labour: Safety and Efficacy. Obstet Gynecol 1997; 89:387-91.
- [13] Mundle WR, Young DC. Vaginal misoprostol for induction of labour. A randomized controlled trial. Obstet Gynaecol 1996; 86: 521-5.
- [14] Varaklis K, Gumina R, Stubblefield PG. Randomised controlled trial of vaginal misoprostol and intracervical prostaglandin E2 gel for induction of labour at term. Obstet Gynaecol 1995; 86: 541-4.
- [15] Sanchez-Ramos L, Kaunitz AM, Wear RL, Delke I, Gaudier FL. Misoprostol for cervical ripening and labour induction. A Meta analysis. Obstet Gynaecol 1997; 89:633-42.
- [16] Lumbiganon P, Hofmeyr J, Gulmezoglu AM, Pinol A, Villar J. Misoprostol dose related shivering and pyrexia in the third stage of labour. Br J Obstet Gynaecol 1999; 106: 304-308.
- [17] Wing DA, Paul RH. A comparison of differing dosing regimens of vaginally administered Misoprostol for preinduction cervical ripening and labour induction. Am J Obstet Gynecol 1996; 175: 158-64.
- [18] Wing DA, Jones MM, Rahall A, Goodwin TM, Paul RH. Misoprostol: An effective agent for cervical ripening and labour induction. Obstet Gynecol 1995b; 172: 1811-6.
- [19] Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of Misoprostol with continuous dinoprostone for cervical ripening and labour induction. Am J Obstet Gynecol 1997; 177:612-8.
- [20] Sanchez-Ramos L, Peterson DE, Delke I, Gaudier FL, Kaunitz AM. Labour induction with prostaglandin E1, misoprostol compared with Dinoprostone vaginal insert: A Randomized trial. Obstet Gynaecol 1998; 91:401-5.